Novo Nordisk Faces Dual Challenges Amid Strategic Shifts
Published on 01/26/2026 at 13:13 | Redaktion boerse-global.de
The Danish pharmaceutical giant Novo Nordisk is navigating a complex period marked by operational restructuring and legal scrutiny. As the company advances the U.S. launch of its oral Wegovy tablet, it confronts new job cuts and a significant antitrust lawsuit related to its diabetes portfolio.
A new legal challenge emerged last Friday when a class-action lawsuit was filed against Novo Nordisk in a U.S. federal court in New York. The complaint alleges anticompetitive practices concerning the diabetes drug Victoza.
Plaintiffs accuse Novo Nordisk and Teva Pharmaceuticals of engaging in a “pay-for-delay” agreement. This alleged deal purportedly pushed back the market entry of more affordable generic versions until Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
